A team of scientists and drug developers with decades of early-stage antiviral experience and demonstrated success, and the founders of READDI, the global non-profit that mobilized nearly $100M for antiviral drug discovery.
36 years experience in biopharma, including 30 years at Eli Lilly and Company. Led Eshelman Innovation at UNC-CH from $100M gift to University from Dr Fred Eshelman. Interim-CEO of READDI at its foundation. Leading strategy and fundraising.
LinkedIn ↗Over 20 years of successful academic virology experience. Co-founder of READDI in 2020. Leads scientific strategy and operations.
LinkedIn ↗Experienced drug developer with deep expertise in operations, clinical planning and portfolio management.
LinkedIn ↗Chief Medical Officer with over 30 years of drug development expertise in biopharma, including virology.
LinkedIn ↗Experienced program manager with a background in antiviral drug discovery and preclinical development.
LinkedIn ↗Industry leaders supporting Virentis Bio across drug development, regulatory strategy, and commercialization.
Over 30 years of successful academic virology experience. Co-founder of READDI in 2020. Scientific advice on current portfolio.
LinkedIn ↗Over 20 years of successful academic virology experience. Deep knowledge of lead asset. Scientific advice on current portfolio.
LinkedIn ↗Chief Scientific Officer at Invivyd. 20 years of virology drug development experience in biotech.
LinkedIn ↗The Virentis team founded READDI, a global non-profit launched during the COVID-19 pandemic to advance antiviral drugs against future viral threats, raising almost $100M for that effort and building a well-developed global network driven by a passion to solve global viral threats.
